{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:00:04Z","timestamp":1780610404567,"version":"3.54.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,11,18]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Protein kinases are conserved enzymes that catalyse the phosphorylation process in cells.\nThey are recognized as the targets for many diseases. The FDA has approved many kinase inhibitors\nfor the treatment of cancer and confirmed kinases as relevant targets for drug discovery. Major approved\ndrugs are ATP competitive reversible non-covalent inhibitors that achieve selectivity by recognition\nof specific binding pockets of targeted kinases. In recent years, scientists have paid attention on\ndeveloping irreversible covalent kinase inhibitors to achieve better selectivity, less toxicity and side effects.\nSince 2013, seven Irreversible Kinase Inhibitors (IKIs), including; afatinib, ibrutinib, neratinib,\ndacomitinib, osimertinib, acalabrutinib and zanubrutinib have been approved by the FDA for treatment\nof severe diseases, like; Metastatic Non-Small Cell Lung Cancer (NSCLC), Mantle Cell Lymphoma\n(MCL) and HER2-positive breast cancer. These inhibitors target the cysteine residues of kinases.\nMany IKIs that target cysteine residues are in clinical trials for different diseases and are yet to be\napproved. We have reviewed the research done and efforts made for finding novel cysteine targeted\nIKIs as drugs in the recent years.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557520666200513121524","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:11:25Z","timestamp":1589371885000},"page":"1732-1753","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0793","authenticated-orcid":true,"given":"Debasis","family":"Das","sequence":"first","affiliation":[{"name":"Discovery Chemistry Research, ArromaxPharmatech Co. Ltd. Sangtian Island Innovation Park, No. 1 Huayun Road, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hong","sequence":"additional","affiliation":[{"name":"Discovery Chemistry Research, ArromaxPharmatech Co. Ltd. Sangtian Island Innovation Park, No. 1 Huayun Road, Suzhou 215123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T15:45:14Z","timestamp":1605714314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181924\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":0,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,11,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666200513121524","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}